Abstract: Objective To investigate the efficacy and economic benefits of ganglioside combined with murine nerve growth factor in the treatment of patients with acute cerebral hemorrhage. Methods A total of 240 patients with acute cerebral hemorrhage admitted from June, 2015 to June, 2017 in our department were divided into observation group (ganglioside combined with mouse nerve growth factor) and control group (mouse nerve growth factor alone). The effective rate of clinical efficacy, quality of life and drug cost were compared between the two groups. Results The effective rate of patients in the observation group was higher than that of control group two weeks after the treatment (χ²=4.148, P=0.042). The volume of intracranial hemorrhage in the observation group and control group decreased after 2 weeks of treatment, but the reduction in the observation group was larger than that in the control group (t=13.000, P<0.001). After 2 weeks of treatment, the edema area around the hematoma of the observation group and the control group decreased, but the reduction in the observation group was larger than that of the control group (t=7.856, P<0.001). There was no significant difference in IL-6 level between the two groups before the treatment (t=0.178, P=0.867). After 2 weeks of treatment, the levels of IL-6 in both groups decreased and the decrease in the observation group was statistically significant significance of learning (t=7.170, P<0.001); There was no significant difference in ADL score between the two groups before the treatment (P>0.05). After 3 months of treatment, the ADL score of the observation group was significantly higher than that of the control group (P<0.05). The days of hospitalization in the observation group were lower than those in the control group, with significant difference[(13.9±4.2) d vs. (25.8±6.4) days, t=17.030, P<0.01). There was no significant difference in medication spending between the two groups (5 764.3±1 002.9) vs (5 499.7±998.5), t=1.875, P=0.062]. Conclusion The combination of ganglioside and murine nerve growth factor in the treatment of acute intracerebral hemorrhage can significantly improve the patient's condition and quality of life, and does not significantly increase the economic burden on patients, it is worth in the clinical application.